Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study

• Published in: Schizophrenia bulletin Vol. 48; no. 1; pp. 166 - 175
• Main Authors: Solmi, Marco, Tiihonen, Jari, Lähteenvuo, Markku, Tanskanen, Antti, Correll, Christoph U, Taipale, Heidi
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 21.01.2022
• Subjects: Adrenergic beta-Antagonists - administration & dosage; Adrenergic beta-Antagonists - therapeutic use; Adult; Antidiabetics; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - therapeutic use; Antihypertensives; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - therapeutic use; Antipsychotics; Beta blockers; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - epidemiology; Comorbidity; Female; Finland - epidemiology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Male; Medication Adherence - statistics & numerical data; Metabolic Diseases - drug therapy; Metabolic Diseases - epidemiology; Middle Aged; Mortality; Psychotropic drugs; Regular; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - epidemiology; Within-subjects design; Finland; cardiovascular disease; cholesterol; psychiatry; physical health; diabetes; adherence

Abstract Background People with schizophrenia/schizoaffective disorder (schizophrenia) die early, largely due to cardiovascular-related mortality. Antipsychotics are associated with lower mortality. We aimed to explore whether antipsychotic use can reduce discontinuation of medications for cardiovas...